Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TAK and other ETFs, options, and stocks.

About TAK

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following business divisions: Gastrointestinal Diseases, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, and Neuroscience The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan. 

CEO
Julie So-Young Kim
CEOJulie So-Young Kim
Employees
47,029
Employees47,029
Headquarters
Osaka, Osaka
HeadquartersOsaka, Osaka
Founded
1781
Founded1781
Employees
47,029
Employees47,029

TAK Key Statistics

Market cap
57.90B
Market cap57.90B
Price-Earnings ratio
-54.97
Price-Earnings ratio-54.97
Dividend yield
3.21%
Dividend yield3.21%
Average volume
2.40M
Average volume2.40M
High today
—
High today—
Low today
—
Low today—
Open price
$18.42
Open price$18.42
Volume
0.00
Volume0.00
52 Week high
$19.10
52 Week high$19.10
52 Week low
$12.99
52 Week low$12.99

TAK News

TipRanks 1d
Takeda reports new data from Phase 3 LATITUDE psoriasis studies of zasocitinib

Takeda (TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib, an investigational, next-generation, highly selective and potent o...

Nasdaq 1d
Takeda's Zasocitinib Shows Superior Skin Clearance In Phase 3 Psoriasis Trial

(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK,4502.T) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279) in adults...

Takeda's Zasocitinib Shows Superior Skin Clearance In Phase 3 Psoriasis Trial
TipRanks 2d
Keros Therapeutics to receive $20M development milestone payment from Takeda

Keros Therapeutics (KROS) announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of elriterce...

Analyst ratings

59%

of 17 ratings
Buy
58.8%
Hold
41.2%
Sell
0%

More TAK News

Simply Wall St 5d
Will Priority Review Change Takeda Stock's Narrative - simplywall.st

...

Will Priority Review Change Takeda Stock's Narrative - simplywall.st

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.